Hearing · house
"The Role of Pharmacy Benefit Managers"
2024-09-11 · 18:00
Source status: Scheduled
Committee
Location
2141, Rayburn House Office Building
Video
Witnesses
Dr. Richard Frank
Director, Health Program
Dr. T. Joseph Mattingly II
Associate Professor and Vice Chair of Research, College of Pharmacy
Dr. Anthony LoSasso
Professor and Chair, Department of Economics
Dr. Karen Van Nuys
Executive Director, Value of Life Sciences Innovation
Official published hearing
Congress.gov explicitly associates this publication with this proceeding.
H.Hrg.118
THE ROLE OF PHARMACY BENEFIT MANAGERS
2024-09-11 · GovInfo record 2024-11-25
Congress.gov lists this publication among several possible proceedings.
Documents
Witness documents
- Witness Biography · PDF
- Witness Statement · PDF
- Witness Biography · PDF
- Witness Biography · PDF
- Witness Truth in Testimony · PDF
- Witness Statement · PDF
- Witness Truth in Testimony · PDF
- Witness Truth in Testimony · PDF
- Witness Truth in Testimony · PDF
- Witness Biography · PDF
- Witness Statement · PDF
- Witness Statement · PDF
Hearing record
- Response to the question for the record from Dr. LoSasso · Hearing: Questions for the Record · PDF
- Response to the question for the record from Dr. Van Nuys · Hearing: Questions for the Record · PDF
- Response to the question for the record from Dr. Frank · Hearing: Questions for the Record · PDF
- Response to the question for the record from Dr. Mattingly · Hearing: Questions for the Record · PDF
- A question for the record to all witnesses, submitted for the Record by Mr. Correa of CA · Hearing: Questions for the Record · PDF
Committee activity
- An article from the Wall Street Journal titled, “Mail-Order Drugs Were Supposed to Keep Costs Down. It’s Doing the Opposite.”, submitted for the Record by Mr. Correa of CA · Support Document · PDF
- An article from The New York Times titled, “The Opaque Industry Secretly Inflating Prices for Prescription Drugs”, submitted for the Record by Mr. Correa of CA · Support Document · PDF
- A report from the Federal Trade Commission titled, “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies”, submitted for the Record by Mr. Correa of CA · Support Document · PDF
- A letter dated June 5, 2024, from PhRMA to Assistant Attorney General Kanter, Secretary Becerra, and Chair Khan regarding the consolidation of the health care market, submitted for the Record by Mr. Correa of CA · Support Document · PDF
- A statement of dissent dated July 9, 2024, from Commissioner Melissa Holyoak of the Federal Trade Commission in the matter of the Pharmacy Benefit Managers Report, submitted for the Record by Mr. Moran of TX · Support Document · PDF
- A report from Brookings titled, “A brief look at current debates about pharmacy benefit managers”, submitted for the Record by Mr. Correa of CA · Support Document · PDF
- A letter from California Life Sciences and California Pharmacists Association to members of the California Congressional Delegation regarding PBM reforms, submitted for the Record by Mr. Correa of CA · Support Document · PDF
- A report from Compass Lexecon titled, “PBMs and Prescription Drug Distribution: An Economic Analysis of Criticisms Levied Against Pharmacy Benefit Managers”, submitted for the Record by Mr. Correa of CA · Support Document · PDF
- A report from Drug Channels Institute titled, “The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers”, submitted for the Record by Mr. Correa of CA · Support Document · PDF
Source: https://api.congress.gov/v3/committee-meeting/118/house/117633